• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pandemic Makes One-Fifth of Cancer Patients Less Willing to Take on Trials

Pandemic Makes One-Fifth of Cancer Patients Less Willing to Take on Trials

November 16, 2020

A new survey shows one in five cancer patients are far less likely to participate in future clinical trials due to fear of COVID-19 exposure, raising the question of whether enrollment levels that have dropped precipitously since the beginning of the pandemic are likely to recover after the virus is controlled.

In an attempt to answer that question, researchers at the American Cancer Society (ACS) conducted the survey in response to a report from the SWOG Cancer Research Network that showed the enrollment rate in its trials had slowed from 76.5 percent in the first weeks of 2020 to only 23.5 percent since March 15.

ACS surveyed more than 3,000 members of its Cancer Action Network Survivor Views panel in May and June and found that, while 80 percent of respondents said that COVID-19 had made no change in their view of participating in a clinical trial, the remaining respondents (18.1 percent) were more than seven times less likely to enroll. 

According to the ACS report, published last week on the JAMA Network, the most common reasons cited by respondents who were less likely to enroll were fear of exposure to COVID-19 (70 percent) and difficulty accessing normal care during the pandemic (18 percent). Reluctance to leave their home/family and financial hardship caused by the pandemic were cited by about 10 percent of respondents.

ACS also reported that almost 34 percent of survey respondents said they had discussed a clinical trial with their physician and 20 percent were offered a trial. Of those offered a trial, 78 percent accepted and 12 percent eventually enrolled.

Response patterns were the same across gender, race and socioeconomic subpopulations, ACS said, which included 73 percent female, 3.6 percent African American and 36.6 percent with an annual household income of $60,000 or less. 

Read the report here: https://bit.ly/2GZ327a. 

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing